Synlogic, Inc.
SYBX Healthcare Biotechnology
Synlogic, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $8,000.00, down 99.8% from fiscal 2023. In the quarter to June 2026, EPS was flat and free cash flow fell 277.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow SYBX
Synlogic, Inc. (SYBX) Altman Z-score
Synlogic, Inc.'s Altman Z-score for fiscal 2024 is −35.79, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2024 | −35.79 | (26.33) |
| FY2023 | −9.45 | (4.84) |
| FY2022 | −4.61 | (4.92) |
| FY2021 | 0.30 | 1.49 |
| FY2020 | −1.18 | (1.25) |
| FY2019 | 0.06 | (4.74) |
| FY2018 | 4.80 | 3.50 |
| FY2017 | 1.30 | 4.37 |
| FY2016 | −3.08 | — |
How fiscal 2024’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.64 | — | 0.77 | |
| Retained earnings / total assets | (22.28) | — | −31.19 | |
| EBIT / total assets | (2.07) | — | −6.82 | |
| Market value of equity / total liabilities | 2.41 | — | 1.45 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −35.79 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −80.41 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| NIKI Niki BioSolutions, Inc. compare | −5.0× |
| CLGN CollPlant Biotechnologies Ltd. Sponsored ADR compare | −16.9× |
| SYBX Synlogic, Inc. | −35.8× |
| AIM AIM ImmunoTech Inc. compare | −114× |
| TCRT Alaunos Therapeutics, Inc. compare | −436× |
| BCLI Brainstorm Cell Therapeutics Inc. compare | — |
| FBLG FibroBiologics Inc. compare | — |
| SKYE Skye Bioscience, Inc. compare | — |
| ACXP Acurx Pharmaceuticals, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets